Methods of modulating SMYD3 for treatment of cancer

Details Methods of modulating SMYD3 for treatment of cancer Methods of modulating SMYD3 for treatment of cancer

2011-06-28

2011-06-28

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Reexamination Certificate

active

07968281

ABSTRACT:
The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.

REFERENCES:
patent: 5910444 (1999-06-01), Masuta et al.
patent: 2004/0235018 (2004-11-01), Nakamura et al.
patent: 2009/0035303 (2009-02-01), Nakamura et al.
patent: 2009/0142344 (2009-06-01), Nakamura et al.
patent: 2009/0175844 (2009-07-01), Nakamura et al.
patent: 2010/0184088 (2010-07-01), Nakatsuru
patent: 2010/0248240 (2010-09-01), Nakamura et al.
patent: 1 303 933 (2001-07-01), None
patent: 0 390 530 (1990-10-01), None
patent: 2004 264294 (2004-09-01), None
patent: WO 00/17355 (2000-03-01), None
patent: WO 00/44900 (2000-08-01), None
patent: WO 02/059377 (2002-08-01), None
patent: WO 02/090578 (2002-11-01), None
patent: WO 02/092002 (2002-11-01), None
patent: WO 03/010180 (2003-02-01), None
patent: WO 03/027143 (2003-04-01), None
patent: WO03027143 (2003-04-01), None
patent: WO 2004/076623 (2004-09-01), None
patent: WO 2005/071102 (2005-08-01), None
patent: WO 2008/152816 (2008-12-01), None
Hamamoto et al, Nature Cell Biology, vol. 6, p. 731-740, 2004.
Vandel et al, Mol & Cell Bio, 21:6484-6494, 2001.
Hamamoto et al Nat Cell Bio, 6: 731-740, 2004.
Sequence search result (Nakamura-Hamamoto)., 2010.
Hamamoto, R., et al., “SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells,”Nature Cell Biology, vol. 6(8), pp. 731-740 (Jul. 4, 2004).
Database Geneseq [Online], “Human muscle BOP protein 41,” EBI Accession No. GSP:AAG66728, abstract, Database Accession No. AAG66728, abstract (Nov. 26, 2001).
Du et al. “Hypermethylation in Human Cancers of theRIZ1Tumor Suppressor Gene, a Member of a Histone/Protein Methyltransferase Superfamily,” Nov. 15, 2001, Cancer Res., 61(22): 8094-8099.
Echeverri et al., “siRNA Design: It's All the Algorithm,” Oct. 3, 2004, Ambion TechNotes 11 (http:/www.ambion.com/techlib/tn/113/14.html).
Database NCBI, [Online] “Homo sapienscDNA: FLJ21080 fls, clone CAS02449” EMBL Accession No. AK024733: Sep. 29, 2000.
Database NCBI, [Online] “AL557360Homo sapiensT Cells (Jurkat Cell Line)Homo sapienscDNA clone CS0DH004YB15 5-Prime, mRNA,” EMBL Accession No. AL557360: Feb. 11, 2001.
Firestein et al., “Set Domain-Dependent Regulation of Transcriptional Silencing and Growth Control by SUV39H1, a Mammalian Ortholog ofDrosophilaSu(var)3-9,” Jul. 2000, Mol. Cell Biol., 20(13): 4900-4909.
Fu T.B., et al., “The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates,” Dec. 1993, J. Virol., 67(12); 6965-6972.
Database NCBI, [Online], “Homo sapiensSET and MYND domain containing 3, mRNA (cDNA clone MGC:32757 Image:4334047), complete cds,” GenBank Accession No. BC031010, Jun. 13, 2002.
Database Genecards [Online] Accession No. GC01M242239: Jan. 1, 2004.
Hamamato et al., Proceedings/Annual Meeting of the American Association for Cancer Research/ Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting (43): 13-13: Mar. 1, 2002.
Hamamoto et al., “Enhanced SMYD3 expression is essential for the growth of breast cancer cells,” Feb. 2006, Cancer Sci. 97(2): 113-118.
Hammato et al., 2001, Jpn. J. Cancer Res. (proceedings Sixtieth Annual Meeting of the Japanese Cancer Association), 92(Supplement): 117(208).
Kato et al., 2002, Jpn. J. Cancer Res. (proceedings Sixty-First Annual Meeting of the Japanese Cancer Association), 93(Supplement): 78(2033).
Luking et al., “The protein family of RNA helicases,” 1998, Crit. Rev. Biochem Mol. Biol., 33(4): 259-296.
Nakajima et al., “RNA helicase A mediates association of CBP with RNA polymerase II,” Sep. 19,1997, Cell, 90(6), 1107-1112.
Nozaki et al., 2004, The American Association For Cancer Research/AACR; 45: 213(#934).
Okabe et al., “Genome-wide Analysis of Gene Expression in Human Hepatocellular Carcinomas Using cDNA Microarray: Identification of Genes Involved in Viral Carcinogenesis and Tumor Progression,” Mar. 1, 2001, Cancer Res.,61(5): 2129-2137.
Rea et al., “Regulation of chromatin structure by site-specific histone H3 methyltransferases,” Aug. 10, 2000, 406(6796): 593-599.
Rozoviskaia et al., “Self-association of the SET domains of human ALL-1 and ofDrosophilaTRITHORAX and ASH1 Proteins,” Jan. 20, 2000, Oncogene, 19(3): 351-357.
Shibuya et al., “Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis,” Sep. 30, 2006, J. Biochem. Mol. Biol., 39(5): 469-478.
Stockand et al., “S-Adenosyl-L-homocysteine Hydrolase Regulates Aldosterone-induced Na+Transport,” Feb. 5, 1999, J. Biol. Chem., 274(6): 3842-3850.
Strahl et al., “Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei inTetrahymena,” Dec. 21, 1999, Proc. Natl. Acad. Sci. U.S.A., 96(26): 14967-14972.
Strausberg et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,” Dec. 24, 2002, Proc. Natl. Acad. Sci. U.S.A., 99(26): 16899-16903.
Tsuge et al., “A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5′ flanking region of SMYD3 is a risk factor for human cancers,” Oct. 2005, Nat. Genet. 37(10): 1104-1107. Epub Sep. 11, 2005.

Affiliated with

Also associated with

Rating

Methods of modulating SMYD3 for treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of modulating SMYD3 for treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating SMYD3 for treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2650034